Cartesian Therapeutics Inc. (RNAC) Insider Trading

Last 12 months

Insiders bought $206k and sold $259k on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market

−$53k

1 buy · 3 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 3

executives and directors

Last open-market buy

Dec 2025

Dec 4, 2025

Get an email when RNAC's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jan 6	Carsten Brunn President and CEO	SoldNo plan	23,766	$6.82	$162k	6.8%	Form 4
Jan 6	Milos Miljkovic Chief Medical Officer	SoldNo plan	3,573	$6.82	$24k	5.7%	Form 4
Jan 6	Blaine Davis Chief Financial Officer	SoldNo plan	10,591	$6.82	$72k	8.0%	Form 4
Dec 4, 2025	Timothy C Barabe Director	Bought	30,000	$6.86	$206k	123%	Form 4
Apr 9, 2025 – Apr 11, 2025	Timothy A Springer Director	Bought 10 parts	149,075	$10.21 average	$1.52M	1.5%	Form 4
Mar 18, 2025 – Mar 20, 2025	Timothy A Springer Director	Bought 3 parts	89,863	$15.26 average	$1.37M	1.0%	Form 4
Jan 13, 2025 – Jan 14, 2025	Timothy A Springer Director	Bought 3 parts	20,967	$17.47 average	$366k	0.2%	Form 4
Jan 3, 2025 – Jan 6, 2025	Metin Kurtoglu Chief Technology Officer	SoldNo plan 2 parts	4,875	$16.78 average	$82k	7.3%	Form 4
Jan 3, 2025 – Jan 6, 2025	Milos Miljkovic Chief Medical Officer	SoldNo plan 2 parts	1,880	$16.78 average	$32k	5.0%	Form 4
Jan 3, 2025 – Jan 6, 2025	Christopher M Jewell Chief Scientific Officer	SoldNo plan 2 parts	2,550	$16.78 average	$43k	4.6%	Form 4
Jan 3, 2025 – Jan 6, 2025	Emily English Chief Operations Officer	SoldNo plan 2 parts	1,797	$16.78 average	$30k	4.3%	Form 4
Jan 3, 2025 – Jan 6, 2025	Carsten Brunn President and CEO	SoldNo plan 2 parts	17,271	$16.78 average	$290k	7.8%	Form 4
Jan 3, 2025 – Jan 6, 2025	Blaine Davis Chief Financial Officer	SoldNo plan 2 parts	7,989	$16.78 average	$134k	7.8%	Form 4
Dec 19, 2024 – Dec 23, 2024	Timothy A Springer Director	Bought 5 parts	52,189	$18.49 average	$965k	0.6%	Form 4
Dec 9, 2024 – Dec 10, 2024	Metin Kurtoglu Chief Technology Officer	SoldNo plan 3 parts	13,664	$25.26 average	$345k	21%	Form 4
Nov 19, 2024 – Nov 21, 2024	Metin Kurtoglu Chief Technology Officer	SoldNo plan 4 parts	38,689	$16.78 average	$649k	43%	Form 4
Nov 14, 2024 – Nov 18, 2024	Timothy A Springer Director	Bought 5 parts	431,940	$17.07 average	$7.37M	4.9%	Form 4
Nov 14, 2024 – Nov 18, 2024	Metin Kurtoglu Chief Technology Officer	SoldNo plan 5 parts	82,368	$17.46 average	$1.44M	62%	Form 4
Nov 14, 2024 – Nov 15, 2024	Milos Miljkovic Chief Medical Officer	SoldNo plan 2 parts	55,000	$16.50 average	$907k	75%	Form 4
Nov 14, 2024 – Nov 15, 2024	Christopher M Jewell Chief Scientific Officer	SoldNo plan 3 parts	52,115	$16.79 average	$875k	67%	Form 4

Jan 6No plan
Carsten Brunn
President and CEO · sold 23,766 at $6.82
$162k
6.8% of stake
Jan 6No plan
Milos Miljkovic
Chief Medical Officer · sold 3,573 at $6.82
$24k
5.7% of stake
Jan 6No plan
Blaine Davis
Chief Financial Officer · sold 10,591 at $6.82
$72k
8.0% of stake
Dec 4, 2025
Timothy C Barabe
Director · bought 30,000 at $6.86
$206k
123% of stake
Apr 9, 2025 – Apr 11, 2025
Timothy A Springer
Director · bought 149,075 at avg $10.21
$1.52M
1.5% of stake
Mar 18, 2025 – Mar 20, 2025
Timothy A Springer
Director · bought 89,863 at avg $15.26
$1.37M
1.0% of stake
Jan 13, 2025 – Jan 14, 2025
Timothy A Springer
Director · bought 20,967 at avg $17.47
$366k
0.2% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Metin Kurtoglu
Chief Technology Officer · sold 4,875 at avg $16.78
$82k
7.3% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Milos Miljkovic
Chief Medical Officer · sold 1,880 at avg $16.78
$32k
5.0% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Christopher M Jewell
Chief Scientific Officer · sold 2,550 at avg $16.78
$43k
4.6% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Emily English
Chief Operations Officer · sold 1,797 at avg $16.78
$30k
4.3% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Carsten Brunn
President and CEO · sold 17,271 at avg $16.78
$290k
7.8% of stake
Jan 3, 2025 – Jan 6, 2025No plan
Blaine Davis
Chief Financial Officer · sold 7,989 at avg $16.78
$134k
7.8% of stake
Dec 19, 2024 – Dec 23, 2024
Timothy A Springer
Director · bought 52,189 at avg $18.49
$965k
0.6% of stake
Dec 9, 2024 – Dec 10, 2024No plan
Metin Kurtoglu
Chief Technology Officer · sold 13,664 at avg $25.26
$345k
21% of stake
Nov 19, 2024 – Nov 21, 2024No plan
Metin Kurtoglu
Chief Technology Officer · sold 38,689 at avg $16.78
$649k
43% of stake
Nov 14, 2024 – Nov 18, 2024
Timothy A Springer
Director · bought 431,940 at avg $17.07
$7.37M
4.9% of stake
Nov 14, 2024 – Nov 18, 2024No plan
Metin Kurtoglu
Chief Technology Officer · sold 82,368 at avg $17.46
$1.44M
62% of stake
Nov 14, 2024 – Nov 15, 2024No plan
Milos Miljkovic
Chief Medical Officer · sold 55,000 at avg $16.50
$907k
75% of stake
Nov 14, 2024 – Nov 15, 2024No plan
Christopher M Jewell
Chief Scientific Officer · sold 52,115 at avg $16.79
$875k
67% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RNAC, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

BSPKBespoke Extracts Inc.

ATXIAvenue Therapeutics Inc.

HYPDHyperion DeFi, Inc.

LPCNLipocine Inc.

DAREDare Bioscience Inc.

CPMDCannapharmaRx Inc.

SCPXScorpius Holdings Inc.

LGVNLongeveron Inc.

Spot a number that looks wrong? Check it in RNAC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RNAC

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.